Age at Gluten Introduction Not Linked to Risk of Celiac Disease

This article originally appeared here.
Share this content:
Age at Gluten Introduction Not Linked to Risk of Celiac Disease
Age at Gluten Introduction Not Linked to Risk of Celiac Disease

MONDAY, Jan. 19, 2015 (HealthDay News) -- The age of introduction of gluten is not associated with risk of celiac disease (CD) in genetically predisposed children, according to a study published online Jan. 19 in Pediatrics.

Carin Andrén Aronsson, from Lund University in Sweden, and colleagues examined the correlation between age of gluten introduction and risk of CD in genetically predisposed children. Data were collected for 6,436 newborn infants who were screened for high-risk HLA-genotypes for CD, and followed-up in Finland, Germany, Sweden, and the United States.

The researchers found that Swedish children were introduced to gluten earlier than those from Finland, Germany, and the United States (median, 21.7 weeks versus 26.1, 30.4, and 30.4 weeks, respectively; P < 0.0001). Twelve percent of children developed tissue transglutaminase autoantibodies (tTGA) and 5 percent developed CD during a median follow-up of five years. The risk of tTGA and CD was increased for Swedish children compared with U.S. children (hazard ratios, 1.74 and 1.76, respectively). After adjustment for country, HLA, gender, and family history of CD, gluten introduction before 17 weeks or later than 26 weeks was not associated with increased risk for tTGA or CD.

"Time to first introduction of gluten is not an independent risk factor for developing CD by 5 years of age, neither on an overall level nor on a country level comparison," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths